Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus

NCT00391196 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00391196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00391196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2006
Completion date
January 31, 2009
Enrollment
975 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

obesity